Skip to content

Explore the mechanism of acupuncture achieving integrative body-mind regulation for patients with allergic rhinitis from the aspect of hypothalamic-pituitary-adrenal axis

The effect of Mind regulating acupuncture method on immunological parameters of the hypothalamic–pituitary–adrenal axis in patients with allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009082
Enrollment
Unknown
Registered
2016-08-22
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Interventions

A:with Mind regulating acupuncture method and Rhinocort Nasal Spray
B:with conventional acupuncture and Rhinocort Nasal Spray
C:with Rhinocort Nasal Spray

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Subject has experienced main symptoms (nasal congestion, rhinorrhea, sneezing and nasal itching)for more than 4 days a week and for more than 4 consecutive weeks; 2. Subject presenting moderate/severe condition meeting the diagnostic criteria; 3. Subject responding with positive skin test reaction to at least one inhaled allergen; 4. Subject shows a mean total nasal symptom score (TNSS)=4 per week before acupuncture intervention; 5. Subject age ranges between 18 and 65 years old; 6. Subject is able to describe personal willing, provide written informed consent to participant in this trial.

Exclusion criteria

Exclusion criteria: 1. Patient has suffered from acute paranasal sinusitis or upper respiratory infection within the lastest 14 days; signs of chest inflammation showed in X-ray; 2. Patient with history of chronic paranasal sinusitis or chronic paranasal sinusitis showned by accessory nasal cavity X-ray examination; 3. Patient presenting organic nasal cavity disease or has undergone nasal cavity surgery; 4. Patient suffering from paroxysmal respiratory diseases such as asthma; 5. Patients taking H1 antihistamine, steroids, antihistamine, decongestant (nasal, oral or ophthalmic), corticosteroids, antibiotics, or prohibited medications listed in Appendix 1 within 14 days of enrollment; 6. Subject that received specific immunotherapy or systematic hormone therapy in the last year; 7. Subject that received acupuncture, moxibustion, cupping, nasal inhalation of herbal medicine, or other physical therapies in traditional medicine treatment within the last 14 days; 8. Subject that took herbal preparation for allergic rhinitis within the last 14 days; 9. Subject is pregnant, lactating or planning to become pregnant. 10. Subject suffering from tuberculosis, hepatitis, or with blood Cr, AST/ALT values twice higher than normal ranges; 11. Subject suffering from mental disorders; 12. Subject presenting with a smoking history of over 10 cigarettes daily, during 10 consecutive years; 13. Subject presenting scars on the needling location or suffering from systemic disease therefore being considered unsuitable for needling application; 14. Subject that has been estimated as unable to collaborate in the trial.

Design outcomes

Primary

MeasureTime frame
VAS Score for nasal symptoms;rhinoconjunctivitis quality of life questionnaire;CRH;ACTH;CORT;IL-4;IFN-?;

Countries

China

Contacts

Public ContactChen sheng

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

qdchensheng@126.com+86 18810621235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026